A Phase 3 Study of I-Metaiodobenzylguanidine or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Germ Cell Tumours
  • Age: Between 11 - 45 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients who have a diagnosis of neuroblastoma or ganglioneuroblastoma. 2) Patients who are recognized to have high risk disease must have had no prior systematic therapy.

You may not be eligible for this study if the following are true:

  • 1) Patients who have an INRG Stage L2 tumor without amplification of MYCN regardless of tumor histology. 2) Patients with bone marrow failure syndromes.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.